[go: up one dir, main page]

BRPI0517398A - proteìna isolada, seqüência nucleotìdica, vetor, célula de mamìfero, animal transgênico não humano, sondas ou iniciadores, métodos para determinar a presença ou a ausência da variante g1849t do gene jak2, para detectar a presença ou a ausência da variante jak2 v617f, anticorpo monoclonal, hibridoma, kit, sirna, processos permitindo determinar a inibição especìfica de jak2 v617f, de triagem, para a identificação de candidatos medicamentos, utilização de sirna, e, composição - Google Patents

proteìna isolada, seqüência nucleotìdica, vetor, célula de mamìfero, animal transgênico não humano, sondas ou iniciadores, métodos para determinar a presença ou a ausência da variante g1849t do gene jak2, para detectar a presença ou a ausência da variante jak2 v617f, anticorpo monoclonal, hibridoma, kit, sirna, processos permitindo determinar a inibição especìfica de jak2 v617f, de triagem, para a identificação de candidatos medicamentos, utilização de sirna, e, composição

Info

Publication number
BRPI0517398A
BRPI0517398A BRPI0517398-1A BRPI0517398A BRPI0517398A BR PI0517398 A BRPI0517398 A BR PI0517398A BR PI0517398 A BRPI0517398 A BR PI0517398A BR PI0517398 A BRPI0517398 A BR PI0517398A
Authority
BR
Brazil
Prior art keywords
jak2
sirna
variant
absence
determining
Prior art date
Application number
BRPI0517398-1A
Other languages
English (en)
Inventor
William Vainchenker
Valerie Ugo
Chloe James
Jean-Pierre Le Couedic
Nicole Casadevall
Original Assignee
Assist Publ Hopitaux De Paris
Inst Nat Sante Rech Med
Univ Versailles St Quentin En
Univ Paris Sud
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34953071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assist Publ Hopitaux De Paris, Inst Nat Sante Rech Med, Univ Versailles St Quentin En, Univ Paris Sud, Roussy Inst Gustave filed Critical Assist Publ Hopitaux De Paris
Publication of BRPI0517398A publication Critical patent/BRPI0517398A/pt
Publication of BRPI0517398B1 publication Critical patent/BRPI0517398B1/pt
Publication of BRPI0517398B8 publication Critical patent/BRPI0517398B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G01N33/57505—
    • G01N33/57595—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)

Abstract

PROTEìNA ISOLADA, SEQUêNCIA NUCLEOTIDICA, VETOR, CéLULA DE MAMìFERO, ANIMAL TRANSGêNICO NãO HUMANO, SONDAS OU INICIADORES, METODOS PARA DETERMINAR A PRESENçA OU A AUSêNCIA DA VARIANTE G1849T DO GENE JAK2, PARA DETECTAR A PRESENçA OU A AUSêNCIA DA VARIANTE JAK2 V617F, ANTICORPO MONOCLONAL, HIBRILDOMA, KIT, SIRNA, PROCESSOS PERMITINDO DETERMINAR A INIBIçãO ESPECìFICA DE JAK2 V617F, DE TRIAGEM, PARA A IDENTIFICAçãO DE CANDIDATOS MEDICAMENTOS, UTILIZAçãO DE SIRNA, E, COMPOSIçãO. A presente invenção refere-se à variante V617F da proteína tirosina cinase JAK2, a referida variante sendo responsável pela poliglobulia de Vaquez. A invenção refere-se igualmente a um método de diagnóstico em primeira intenção da eritrócitos e da trombocitoses permitindo as relacionar com as síndromes mieloproliferativas ou à detecção nas síndromes mieloproliferativas da variante JAK2 V617F permitindo reclassificar as mesmas em um novo grupo nosológico e à identificação de inibidores específicos e de SiRNA.
BRPI0517398A 2004-10-27 2005-10-26 proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição BRPI0517398B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0411480A FR2877013A1 (fr) 2004-10-27 2004-10-27 Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
FR0411480 2004-10-27
PCT/EP2005/055586 WO2006045827A1 (fr) 2004-10-27 2005-10-26 Identification d'une mutation de jak2 impliquée dans la polyglobulie de vaquez

Publications (3)

Publication Number Publication Date
BRPI0517398A true BRPI0517398A (pt) 2008-10-14
BRPI0517398B1 BRPI0517398B1 (pt) 2021-03-02
BRPI0517398B8 BRPI0517398B8 (pt) 2021-05-25

Family

ID=34953071

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517398A BRPI0517398B8 (pt) 2004-10-27 2005-10-26 proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição

Country Status (20)

Country Link
US (9) US7781199B2 (pt)
EP (2) EP1692281B8 (pt)
JP (3) JP5090171B2 (pt)
KR (1) KR101203003B1 (pt)
CN (1) CN101072870B (pt)
AT (1) ATE382082T1 (pt)
AU (1) AU2005298636B2 (pt)
BR (1) BRPI0517398B8 (pt)
CA (3) CA2754028A1 (pt)
DE (1) DE602005004008T2 (pt)
DK (1) DK1692281T3 (pt)
ES (1) ES2296229T3 (pt)
FR (1) FR2877013A1 (pt)
IL (1) IL182761A0 (pt)
MX (1) MX2007005174A (pt)
PL (1) PL1692281T3 (pt)
PT (1) PT1692281E (pt)
SI (1) SI1692281T1 (pt)
WO (1) WO2006045827A1 (pt)
ZA (1) ZA200703433B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
CN100497657C (zh) * 2006-09-27 2009-06-10 北京大学人民医院 检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针
US20080153097A1 (en) * 2006-11-15 2008-06-26 Eragen Biosciences, Inc. Methods and kits for detecting jak2 nucleic acid
WO2008153900A1 (en) * 2007-06-06 2008-12-18 University Of Florida Research Foundation Kinase inhibitor compounds
EP2119796B1 (en) * 2007-07-13 2014-01-15 ARKRAY, Inc. Probe for detecting mutation in jak2 gene and use thereof
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
EP2272978B1 (en) 2009-07-10 2012-04-18 Biotrin International Limited Highly sensitive rapid isothermal method for the detection of point mutations and SNPs
WO2011067373A1 (fr) * 2009-12-04 2011-06-09 Assistance Publique - Hopitaux De Paris Methode de detection d'une polyglobulie chez un chien
AU2011214254B2 (en) * 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
US20120021413A1 (en) * 2010-04-30 2012-01-26 Arkray, Inc. Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor
CA2805586C (en) * 2010-07-16 2020-09-01 Stichting Vu-Vumc A method of analysing a blood sample of a subject for the presence of a disease marker
EP3483607A1 (en) 2011-03-18 2019-05-15 Stichting VUmc A method of analysing a blood sample of a subject for the presence of a disease marker
JP2013017395A (ja) * 2011-07-07 2013-01-31 Toyobo Co Ltd 骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法
GB201116876D0 (en) * 2011-09-30 2011-11-16 Epistem Ltd Mutational analysis of JAK2
CN103243153B (zh) * 2012-02-10 2014-11-05 复旦大学附属华山医院 Jak2 v617f突变的检测应用
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
WO2014072487A1 (en) 2012-11-08 2014-05-15 Centre National De La Recherche Scientifique (Cnrs) New phosphodeoxyribosyltransferase mutant enzymes and uses thereof
US10106855B2 (en) 2012-11-09 2018-10-23 The Johns Hopkins University Genetic assay to determine prognosis in Polycythemia Vera patients
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
DK2928477T3 (da) 2012-12-07 2019-10-07 Geron Corp Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
WO2014186764A1 (en) 2013-05-16 2014-11-20 Mobelisk Llc Modular tablet case
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
RU2017139122A (ru) * 2015-04-15 2019-05-15 Промедиор, Инк. Способы лечения миелопролиферативных нарушений
HK1254254A1 (zh) 2015-04-23 2019-07-12 奎斯特诊断投资股份有限公司 用於检测骨髓增殖性疾病中calr突变的方法和组合物
AU2016301380B2 (en) * 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CN105441573A (zh) * 2016-01-11 2016-03-30 武汉海吉力生物科技有限公司 用于检测人类jak2基因v617f突变的引物、探针及试剂盒
US20190328857A1 (en) * 2016-06-10 2019-10-31 Io Biotech Aps Calr and jak2 vaccine compositions
UA127701C2 (uk) 2017-07-28 2023-12-06 Джерон Корпорейшн Спосіб лікування мієлодиспластичного синдрому (варіанти)
JP7650798B2 (ja) 2018-11-29 2025-03-25 ジェロン・コーポレーション 骨髄異形成症候群を治療する方法
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4620469A3 (en) 2020-07-02 2025-10-01 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5753441A (en) 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
WO1997003358A1 (en) 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of identifying inhibitors of the jak-stat signal transduction pathway
US5914393A (en) * 1995-12-05 1999-06-22 Incyte Pharmaceuticals, Inc. Human Jak2 kinase
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6821724B1 (en) 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
WO2000018960A2 (en) 1998-09-25 2000-04-06 Massachusetts Institute Of Technology Methods and products related to genotyping and dna analysis
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CN1440287A (zh) * 2000-06-30 2003-09-03 辉瑞大药厂 治疗外周血管疾病、外周神经病和自主神经病的方法
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds
US20050235375A1 (en) * 2001-06-22 2005-10-20 Wenqiong Chen Transcription factors of cereals
US20060240418A1 (en) 2002-05-03 2006-10-26 Diggans James C Canine gene microarrays
AU2003256453A1 (en) 2002-07-03 2004-01-23 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis
WO2004020583A2 (en) 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
US7537891B2 (en) 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
US20060019284A1 (en) 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US20070248961A1 (en) 2006-04-20 2007-10-25 Maher Albitar Methods for detecting mutations in JAK2 nucleic acid
EP2525651A4 (en) * 2010-01-22 2013-12-11 Chromatin Inc NEW CENTROMERE AND METHOD FOR THEIR USE

Also Published As

Publication number Publication date
US10563200B2 (en) 2020-02-18
JP5090171B2 (ja) 2012-12-05
AU2005298636B2 (en) 2009-11-26
CN101072870A (zh) 2007-11-14
US7429456B2 (en) 2008-09-30
EP1692281A1 (fr) 2006-08-23
MX2007005174A (es) 2007-10-10
ES2296229T3 (es) 2008-04-16
JP5290884B2 (ja) 2013-09-18
JP2008517613A (ja) 2008-05-29
IL182761A0 (en) 2007-07-24
DE602005004008T2 (de) 2009-02-12
CA2585062C (fr) 2012-11-20
JP2013135673A (ja) 2013-07-11
CA2647086A1 (fr) 2006-05-04
US20120066776A1 (en) 2012-03-15
EP1692281B1 (fr) 2007-12-26
HK1094974A1 (zh) 2007-04-20
BRPI0517398B1 (pt) 2021-03-02
BRPI0517398B8 (pt) 2021-05-25
ZA200703433B (en) 2008-08-27
US8637235B2 (en) 2014-01-28
DE602005004008D1 (de) 2008-02-07
US20130189683A1 (en) 2013-07-25
US20080076135A1 (en) 2008-03-27
US20090162849A1 (en) 2009-06-25
EP1895000A1 (fr) 2008-03-05
KR20070104338A (ko) 2007-10-25
US20200140863A1 (en) 2020-05-07
US20150051263A2 (en) 2015-02-19
US20220042016A1 (en) 2022-02-10
DK1692281T3 (da) 2008-05-13
AU2005298636A1 (en) 2006-05-04
US20060288432A1 (en) 2006-12-21
CA2647086C (fr) 2012-09-18
KR101203003B1 (ko) 2012-11-21
JP2009278982A (ja) 2009-12-03
CA2585062A1 (fr) 2006-05-04
CA2754028A1 (fr) 2006-05-04
ATE382082T1 (de) 2008-01-15
PL1692281T3 (pl) 2008-06-30
PT1692281E (pt) 2008-02-06
EP1692281B8 (fr) 2008-02-13
US7781199B2 (en) 2010-08-24
FR2877013A1 (fr) 2006-04-28
US8852931B2 (en) 2014-10-07
JP6103691B2 (ja) 2017-03-29
US20140249204A1 (en) 2014-09-04
US8466338B2 (en) 2013-06-18
US11162100B2 (en) 2021-11-02
US20190323007A1 (en) 2019-10-24
CN101072870B (zh) 2013-01-30
US10364430B2 (en) 2019-07-30
WO2006045827A1 (fr) 2006-05-04
SI1692281T1 (sl) 2008-04-30

Similar Documents

Publication Publication Date Title
BRPI0517398A (pt) proteìna isolada, seqüência nucleotìdica, vetor, célula de mamìfero, animal transgênico não humano, sondas ou iniciadores, métodos para determinar a presença ou a ausência da variante g1849t do gene jak2, para detectar a presença ou a ausência da variante jak2 v617f, anticorpo monoclonal, hibridoma, kit, sirna, processos permitindo determinar a inibição especìfica de jak2 v617f, de triagem, para a identificação de candidatos medicamentos, utilização de sirna, e, composição
Routhier et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas
Xu et al. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis
Volpe et al. Imatinib resistance in CML
IL291633B1 (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
US20170027928A1 (en) Camkk-beta as a target for treating cancer
WO2008124670A3 (en) Compositions and methods for the identification of a carbapenemase gene
CN105980555A (zh) 作为胃癌的责任因子的新型融合基因
Zhao et al. Overexpression of miRNA-143 inhibits colon cancer cell proliferation by inhibiting glucose uptake
Rebollo et al. ESM-1 siRNA knockdown decreased migration and expression of CXCL3 in prostate cancer cells
Guan et al. RNA‐binding protein RBM38 inhibits colorectal cancer progression by partly and competitively binding to PTEN 3′ UTR with miR‐92a‐3p
Hoffmeister et al. Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression
WO2013024144A1 (en) Markers for susceptibility to an inhibitor of an src-family kinase
Hirashita et al. Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells
EP4493726A1 (en) Cancer diagnostics and treatment by means of prmt5 inhibitor
Meng et al. Effects of lncRNA LINC01320 on proliferation and migration of pancreatic cancer cells through targeted regulation of miR‐324‐3p
ES2827241T3 (es) Estado de metilación del ADN como un biomarcador del consumo y la abstinencia del alcohol
CN107326067A (zh) 一种非酒精性脂肪肝的miRNA标记物
Kulkarni et al. TMEM16A partners with mTOR to influence pathways of cell survival, proliferation, and migration in cholangiocarcinoma
WO2014133071A1 (ja) Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
US9274120B2 (en) Stratification of pancreatic and ovarian cancer patients for susceptibility to therapy with PTK2 inhibitors
KR20200037182A (ko) 대장암 환자의 항암제 치료 반응성 예측용 마커
US10363322B2 (en) Non-alcoholic fatty liver regulator 14-3-3 protein
Campanella et al. Lack of microsatellite instability in gastrointestinal stromal tumors
Li et al. Krüppel‐Like Factor 2 Is a Gastric Cancer Suppressor and Prognostic Biomarker

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/12 , C12Q 1/68 , G01N 33/53

Ipc: C12N 9/12 (2006.01), C12Q 1/68 (2006.01), G01N 33/

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE PARIS-SACLAY (FR)